PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Lo	Complete if Known		
Application Number	To Be Accorded		
Filing Date	01/03/2002		
First Named Inventor	Norbert Hauel		
Art Unit	1626		
Examiner Name	R. Ramsuer		
Attorney Docket Number	5/1265-1-D1		
	Application Number Filing Date First Named Inventor Art Unit		

			U.S. PATI	ENT DOCUMENTS	
Examiner Initials		Document Number  Number - Kind Code <sup>2</sup> (if know	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
7		us- 3,940,422	2-24-76	Harfta ex	
	İ	l us-	0	1	
	•	us-		i - · · · · i	
	i	us-	* * * * *	i - · · · · · · · · · · · · · · · · · ·	
		1	· <del>i</del>	* *	
-	<b> </b> -	US-			
	ļ.	US-			
		US-	.  · · · ·		
	ļ	US-	<u>ļ.</u>		
		US-		<u>.</u>	
		US-	1		
	ĺ	us-	1		
	i	us-	· · · · · ·	i	
	i	US-	1	į	
-	-	US-			
		US-			
	-	US			
		US-			
	L.	US-	ļ		
		us-	I	L	
	i -	ue	1	1	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
Initials	No. <sup>1</sup>	Country Code 3 -Number 4- Kind Code 5 (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear   T <sup>6</sup>	
1		<del>JP</del> 60139646 A2	07/24/1985	Otsuka Pharm. Fact.		
	- 0					
	-				i i i	
					† · · · · · ·	

Examiner Date 2-10-0 Considered Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO To Be Accorded **Application Number** INFORMATION DISCLOSURE 01/03/2002 Filing Date **First Named Inventor** Norbert Hauel STATEMENT BY APPLICANT 1626 Group Art Unit (use as many sheets as necessary) R. Ramsuer **Examiner Name** of Attorney Docket Number 5/1265-1-D1 Sheet

			OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	3		Chemical Abstracts 104:33908	
		-	MEHTA, ET AL; "Benzoquinazolines: Part I-Synthesis of 2-Methyl- & 2-Styryl-3(H, Ph &/or Me)-4-ketoquinazolines & Their Spectral Study":Postgraduate Dept. of Chemistry. Sardar Patel University. 1965, 231-233 NOSSEIR, ET AL; "Action of Grignard Reagents On 2-Styryl-3,1-Benzoxaz-4-Ones And 2-Styryl-3-Alkyl Quinazol-4-Ones"; J. Chem. U.A.R 12. No. 1. 57-68 (1969) BAIN, ET AL; "Synthesis of 2-Substituted-4H-3,1-benzoxazin-4-ones"; Org. 1593-1597	
			GREENSPAN, ET AL; "N-Aryl Cinnamides: A Novel Class of Rigid and Highly Potent Leukotriene B4 Receptor Antagonists"; Bio. & Med. Chem. Ltrs, Vol. 7, No. 7, 949-954, 1997 NOSSEIR, ET AL; "Action of Carbonyl Reagents and Diazo-Methane on 2-Styryl-3,1-Benzoxaz-4-Ones and 2-Styryl-3-Alkylquinazol-4-Ones"; U.A.R. J. Chem., 13, No. 4, 379-390, 1970 MIYAGAWA, ET AL; "A Stress Compound in Oats Induced by Victorin, A Host-Specific Toxin From Helminthosporium Victoriae"; Phytochemistry, Vol. 41, No. 6, 1473-1475, 1996 ISHIHARA, ET AL; "Induction of Hydroxyanthranilate Hydrosycinnamoyl Transferase Activity By Oligo-N-Acetylchitooligosaccharides In Oats"; Phytochemistry, Vol. 47, No. 6, 979-974, 1998 Chemical Abstracts, Vol. 76, 1972, Pg. 356	
-			ISLAM, ET AL; "Synthesis of 3,5 dibromo-2-methoxycinnamoyl derivatives as potent fungistatic agents"; Egypt, J. Chem., 17, No. 6, 779-788, 1974	
			KARMARKAR, ET AL; "Action of Aniline and Other Primary Amines on the Anhydrides of Beta-Arylglutaconic Acids. Part I, Formation and Decarboxylation of Semianilides"; Jour. Indian Chem. Soc., Vol. 30, No. 10, 1953	

Examiner	Par	Date	2 10-62
Signature		Considered	2-10-63

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Control number.

Substitute fo	or form 1449B/PTO			Complete if Known		
NEOF	FORMATION DISCLOSURE	OL COURE	Application Number	To Be Accorded		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	CLOSURE	Filing Date	01/03/2002			
STATI	EMENT BY	Δ	PPI ICANT	First Named Inventor	Norbert Hauel	
•		•		Group Art Unit	1626	
	(use as many sheets as necessary) Examiner Name R. Ramsuer		R. Ramsuer			
Sheet	3	of	3	Attorney Docket Number	5/1265-1-D1	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
7		CROMBIE, ET AL; "The Phytoalexins of Oat Leaves: 4H-3,1-Benzoxazin-4-ones or Amides?"; Tetrahedron Letters, Vol. 31, No. 18, 2647-2648, 1990	
3		JIANG, ET AL; "Synthesis and Biological Evaluation of 2-Styrylquinazolin-4(3H)-ones, a New Class of Antimitotic Anticancer Agents Which Inhibit Tubulin Polymerization": J. Med. Chem. 1990. 33. 1721-1728 NAKAI, ET AL; "New Potent Antagonists of Leukotrienes C4 and D4. 1. Synthesis and Structure-Activity Relationships"; J. Med. Chem. 1988, 31, 84-91	
		Dissert, Seite 50; H. Staudinger, Dissert, Seite 39	
• ()			-
		· · · · · · · · · · · · · · · · · · ·	
	-		
		· · · · · · · · · · · · · · · · · · ·	
			-
Examiner		i/) Date	

Considered ~ 10-03

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.